GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patientâ€™s immune systemâ€™s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The Company also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.

Employees

Sector

Biotechnology & Medical Research

More about the company

11-09	GT Biopharma, Inc. Showcases Preclinical Data for GTB-5550 TriKE and KRAS Inhibitor Combination at SITC 2026 Annual Meeting	CI
09-15	GT Biopharma Receives IND Clearance For GTB-5550 In Multiple Myeloma And Provides Update On Phase 1 Trials	CI

Market Cap	6.93M 6.27M 5.78M 5.24M 9.88M 651M 10.17M 69.42M 27.59M 348M 26M 25.45M 1.11B	P/E 2026 *	-0.36x	P/E 2027 *	-0.48x
Enterprise Value	6.93M 6.27M 5.78M 5.24M 9.88M 651M 10.17M 69.42M 27.59M 348M 26M 25.45M 1.11B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	85.65%	Yield 2026 *	-	Yield 2027 *	-

11-09	GT Biopharma, Inc. Showcases Preclinical Data for GTB-5550 TriKE and KRAS Inhibitor Combination at SITC 2026 Annual Meeting	CI
09-15	GT Biopharma Receives IND Clearance For GTB-5550 In Multiple Myeloma And Provides Update On Phase 1 Trials	CI
09-14	GT Biopharma, Inc. announced that it expects to receive $30 million in funding	CI
09-11	GT Biopharma, Inc. - Special Call
08-14	GT Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-30	GT Biopharma Reports Integration Of AI-Based Tools Across Discovery And Engineering Of Tumor-Targeting NK Cell Engagers And Multi-Domain Proteins	CI
06-08	Gt Biopharma Advances Three Trike Drug Candidates into Human Trials and Doses First Patient in Phase 1 Trial of Gtb-5550	CI
06-01	GT Biopharma, Inc. Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives	CI
05-29	GT Biopharma Advances Three Trike Drug Candidates into Human Trials	CI
05-15	GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-14	GT Biopharma announces first patient dosed in phase 1 trial of GTB-5550, a B7-H3-targeted natural killer (NK) cell engager for solid tumors	RE
05-14	Gt Biopharma Inc Announces First Patient Dosed in Phase 1 Trial of Gtb-5550, A B7-H3-Targeted Natural Killer (Nk) Cell Engager for Solid Tumors	CI
04-07	GT Biopharma, Inc. Enters into Investigator Initiated Clinical Trial Agreement with Regents of the University of Minnesota	CI

05/01/23	EF Hutton Starts GT Biopharma at Hold With $2 Price Target	MT
13/09/22	HC Wainwright Adjusts Price Target on GT Biopharma to $5 From $25, Reiterates Buy Rating	MT
12/08/22	Roth Capital Cuts GT Biopharma to Neutral From Buy, Price Target to $3 From $9	MT
24/01/22	B. Riley Lowers GT Biopharma's Price Target to $18 from $26 After Revising Cost Capital Assumptions, Keeps Buy Rating	MT
24/06/21	GT Biopharma : B. Riley Raises GT Biopharma's PT to $26 from $21, Notes Steady Progress of Dose-Escalation Trial of Lead Asset GTB-3550; Keeps Buy Rating	MT

09-15	GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma	AQ
09-11	GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026	AQ
08-14	GT Biopharma Reports Second Quarter 2026 Financial Results	AQ
06-30	A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs	AQ
06-12	After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell	AQ

Oxis International Stock Euronext Paris

Stocks

US6918294025

Biotechnology & Medical Research

Valuation: Oxis International

Latest news: Oxis International

Last Transcript: Oxis International

Analysts' recommendations: Oxis International

Press Releases: Oxis International

News in other languages: Oxis International

Managers and Directors: Oxis International

Bio Therapeutic Drugs

Financials

Company Profile

30/04/24	Caterpillar deja París, el cacao está menos caliente
30/04/24	Le bric-à-brac de Zonebourse : Caterpillar quitte Paris, le cacao est moins chaud

Manager	Title	Age	Since
Michael Breen CEO	Chief Executive Officer	64	02/03/2022
Alan Urban DFI	Director of Finance/CFO	57	03/06/2024

Director	Title	Age	Since
Michael Breen CHM	Chairman	64	15/12/2021
Charles Casamento BRD	Director/Board Member	79	01/05/2023
Hilary Kramer BRD	Director/Board Member	62	07/05/2025

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+1.10%	-2.67%	+62.79%	+70.47%	68.45B
ARGENX SE	+1.28%	+8.71%	+13.96%	+95.16%	61.31B
LONZA GROUP AG	+0.36%	-0.95%	+20.09%	+99.04%	55.73B
BEONE MEDICINES AG	-0.96%	+7.41%	+10.20%	+108.91%	47.51B
IQVIA HOLDINGS INC.	-1.25%	+2.35%	+22.74%	+38.34%	44.68B
REVOLUTION MEDICINES, INC.	-2.41%	-0.73%	+167.89%	+794.72%	38.14B
CELLTRION, INC.	+1.21%	-2.56%	+20.27%	+52.81%	35.85B
GENMAB A/S	-0.87%	-2.89%	+79.60%	+63.96%	33.05B
INSMED INCORPORATED	-2.22%	+8.56%	-39.26%	+397.14%	25.9B
Average	-0.42%	+2.67%	+39.81%	+191.17%	46B
Weighted average by Cap.	-0.15%	+2.84%	+40.23%	+164.80%

	2026 *	2027 *
Net sales	-	-
Net income	-17.35M -15.69M -14.48M -13.11M -24.74M -1.63B -25.48M -174M -69.08M -872M -65.11M -63.72M -2.78B	-18.11M -16.38M -15.12M -13.69M -25.83M -1.7B -26.6M -181M -72.12M -910M -67.98M -66.53M -2.9B
Net Debt	-	-

End-of-day quote Euronext Paris
- ^EUR	-